Michael Austin Loesche, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Foot | 3 | 2019 | 304 | 0.690 |
Why?
|
| Psoriasis | 1 | 2018 | 939 | 0.400 |
Why?
|
| Wound Healing | 4 | 2019 | 2805 | 0.390 |
Why?
|
| Ultrasonography | 6 | 2021 | 5876 | 0.370 |
Why?
|
| Skin | 3 | 2018 | 4456 | 0.340 |
Why?
|
| Bacteria | 1 | 2018 | 1998 | 0.320 |
Why?
|
| Wound Infection | 2 | 2019 | 247 | 0.300 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2017 | 125 | 0.290 |
Why?
|
| Emergency Medicine | 2 | 2020 | 1112 | 0.230 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 2536 | 0.210 |
Why?
|
| Cholecystitis, Acute | 1 | 2021 | 68 | 0.210 |
Why?
|
| Intracranial Hypertension | 1 | 2020 | 165 | 0.180 |
Why?
|
| Leishmania braziliensis | 1 | 2017 | 19 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 6829 | 0.170 |
Why?
|
| Point-of-Care Systems | 3 | 2020 | 1065 | 0.170 |
Why?
|
| Nomograms | 1 | 2019 | 241 | 0.170 |
Why?
|
| Optic Nerve | 1 | 2020 | 563 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2020 | 259 | 0.160 |
Why?
|
| Emergency Service, Hospital | 6 | 2021 | 7110 | 0.160 |
Why?
|
| Aftercare | 1 | 2021 | 537 | 0.160 |
Why?
|
| Debridement | 1 | 2019 | 497 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2019 | 406 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 11616 | 0.160 |
Why?
|
| RNA, Bacterial | 1 | 2018 | 406 | 0.150 |
Why?
|
| Frail Elderly | 1 | 2020 | 557 | 0.150 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 309 | 0.130 |
Why?
|
| Emergencies | 1 | 2020 | 1171 | 0.130 |
Why?
|
| Fungi | 1 | 2016 | 328 | 0.130 |
Why?
|
| Intestine, Small | 1 | 2019 | 1281 | 0.120 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 1095 | 0.120 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 1250 | 0.120 |
Why?
|
| Markov Chains | 1 | 2016 | 992 | 0.120 |
Why?
|
| Accidental Falls | 1 | 2020 | 985 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 924 | 0.120 |
Why?
|
| Interleukins | 1 | 2015 | 832 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2021 | 2754 | 0.100 |
Why?
|
| Prospective Studies | 7 | 2022 | 49071 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 21640 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 13444 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 4253 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2016 | 8882 | 0.070 |
Why?
|
| Aged | 7 | 2022 | 162271 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2021 | 23739 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2020 | 5322 | 0.050 |
Why?
|
| Middle Aged | 7 | 2022 | 216468 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 327 | 0.050 |
Why?
|
| Female | 11 | 2021 | 375459 | 0.050 |
Why?
|
| Male | 10 | 2021 | 352465 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2021 | 67320 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2020 | 237 | 0.050 |
Why?
|
| Disease Progression | 1 | 2016 | 13204 | 0.050 |
Why?
|
| Humans | 15 | 2022 | 686663 | 0.050 |
Why?
|
| Obesity | 1 | 2021 | 11700 | 0.050 |
Why?
|
| Young Adult | 3 | 2022 | 56052 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 38732 | 0.040 |
Why?
|
| Leishmania major | 1 | 2017 | 65 | 0.040 |
Why?
|
| Inflammation | 1 | 2017 | 9617 | 0.040 |
Why?
|
| Staphylococcus | 1 | 2017 | 143 | 0.040 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2016 | 20 | 0.040 |
Why?
|
| Adult | 6 | 2022 | 211400 | 0.040 |
Why?
|
| Streptococcus | 1 | 2017 | 210 | 0.040 |
Why?
|
| Adolescent | 3 | 2022 | 84957 | 0.040 |
Why?
|
| Cadaver | 1 | 2020 | 1287 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2021 | 807 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 59331 | 0.040 |
Why?
|
| Data Mining | 1 | 2021 | 548 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39737 | 0.040 |
Why?
|
| Workplace | 1 | 2022 | 811 | 0.040 |
Why?
|
| Prognosis | 1 | 2016 | 28923 | 0.040 |
Why?
|
| DNA, Fungal | 1 | 2016 | 316 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 1674 | 0.040 |
Why?
|
| Physical Examination | 1 | 2021 | 1244 | 0.030 |
Why?
|
| Trachea | 1 | 2020 | 1107 | 0.030 |
Why?
|
| Esophagus | 1 | 2020 | 1028 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 33186 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 1254 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3583 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 6464 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 4297 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2017 | 963 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 18495 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 7791 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 23439 | 0.020 |
Why?
|
| Logistic Models | 1 | 2022 | 13807 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 80803 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 13606 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 5044 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15407 | 0.020 |
Why?
|
| Age Factors | 1 | 2021 | 19295 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3557 | 0.020 |
Why?
|
| United States | 2 | 2022 | 65579 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2021 | 60991 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2021 | 12323 | 0.020 |
Why?
|
| Animals | 3 | 2019 | 170849 | 0.010 |
Why?
|
| Time Factors | 1 | 2022 | 42271 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 69278 | 0.010 |
Why?
|